SUBSCRIBE
SUBSCRIBE
News   Drug Development

Afamelanotide Implants Effective For Erythropoietic Protoporphyria, Triemli Hospital Study

October 14, 2010 | 
1 min read

Skin & Allergy News -- GOTHENBURG, Sweden - A resorbable subcutaneous implant of afamelanotide significantly reduced painful phototoxic attacks in patients with erythropoietic protoporphyria in a year-long multinational clinical trial.

Clinical research Phase III Europe
MORE ON THIS TOPIC
Gloved hand holding a vial of mpox vaccine
Vaccines
Bavarian Nordic’s Mpox Shot Shows Antibody Responses Wane After 6 to 12 Months: Study
October 4, 2024
 · 
2 min read
 · 
Tristan Manalac
Podcast
BMS’ Schizophrenia Approval, Pfizer’s Sudden Sickle Cell Withdrawal and Roche’s Pharma Day
October 2, 2024
 · 
1 min read
 · 
Heather McKenzie
3D illustration of human kidneys on a scientific background
Immunology and inflammation
Kezar Reports Four Patient Deaths in Mid-Stage Lupus Nephritis Study, Pauses Enrollment
October 1, 2024
 · 
2 min read
 · 
Tristan Manalac
3D concept photo of gene editing showing a tweezers inserting a DNA fragment into a larger strand
Gene Editing
Gene Editor Prime Medicines Signs BMS Cell Therapy Deal, Reprioritizes Pipeline
September 30, 2024
 · 
2 min read
 · 
Annalee Armstrong